Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (May 2026)
20 slides from Bio-gene Technology's investor presentation, May 26, 2026
Slide 1: Investor Presentation
Bio-Gene Technology Limited | ASX: BGT Investor Presentation Developing new insecticides derived from nature to achieve high impact worldwide. 26 May 2026 www.bio-gene.com.au 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an
Slide 3: Investment Highlights
Investment Highlights Focused development of two new insecticides with strong commercial validation. 01. Two New Actives Two insecticidal compounds derived from nature with novel modes of action: » Flavocide® and Qcide® are derived from a unique sub-type of eucalypt » Effective against some major in
Slide 4: The Global Challenges We Help Solve
The Global Challenges We Help Solve Our products address the demand for effective pest control & sustainable agriculture. Public Health Vector Control Crop Protection The mosquito is “the world’s deadliest animal”1 Pesticides are critical to farming » Causes more human deaths than any other creature
Slide 5: The (Big) Problem of Resistance
The (Big) Problem of Resistance • Pests continue to develop resistance to almost all insecticides with >16,500 individual cases across 339 insecticide types in 20191. • Between 20% to 40% of global crop production is lost to pests annually. • Each year, invasive insects cost the global economy appro
Slide 6: Our Unique Products Derived from Nature
Our Unique Products Derived from Nature Qcide® Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (Gypmie messmate) currently farmed in northern Australia. OMRI Listed (US) 15th harvest in QLD completed in early 2026 Flavocide® Flavocide is based on flavesone
Slide 7: Illustrative Efficacy Data - Flavocide
Illustrative Efficacy Data - Flavocide® Flavocide direct (spray chamber) and residue (surface spray) summary data 24hr Mosquito Test Material Rate KD50 (secs) KD90 (secs) KD100 (secs) Mortality (%) Direct Aedes aegypti spray* Flavesone 50mg/ml 488 633 100 Direct Aedes aegypti spray* Flavesone 25mg/m
Slide 8: Illustrative Efficacy Data - Qcide
Illustrative Efficacy Data - Qcide® Household pests – ants & cockroaches Argentine Ant Red Imported Fire Ant German Cockroach For a range of Qcide-related data also see e: 1. Peter Miller, Bryce Peters (UTS) & Peter May (Bio-Gene) (2022) Qcide: Natural insecticide for the control of flying insects.
Slide 9: Flavocide Development – Studies & First Regulatory Application Timeline
Flavocide® Development – Studies & First Regulatory Application Timeline* The regulatory-enabling studies are now well advanced. 2024 2025 2026 2027 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 OECD 417 Pilot in-vivo metabolism in rats & pharmacokinetics (PK) study (complete) (6 months) (part 1) Estimated first
Slide 10: Bio-Gene’s Business Model and the Insecticide Supply Chain
Bio-Gene’s Business Model and the Insecticide Supply Chain Bio-Gene licenses its technology and supplies the active ingredient (Flavocide or Qcide). Bio-Gene’s commercial partners Active Ingredient Manufacturer Wholesale Wholesaler/ Customer Innovator (Formulation, product Distributor Retailer (Acti
Slide 11: Size of the Global Insecticide Market
Size of the Global Insecticide Market Bio-Gene’s regulatory strategy is to file first in Australia, leverage in other regional territories and to file in other major markets (e.g. US), with Bio-Gene is targeting all four market segments with key partners some accelerated pathways to market. 1st prio
Slide 12: Size of the Global Insecticide Market
Size of the Global Insecticide Market Bio-Gene is targeting all four market segments with key partners Flavocide and Qcide are positioned for use by consumers, inc. home & garden Segment (Est. 2024, US$B) Worldwide % Australia USA Japan EU ROW and household nuisance insect Public health vector contr
Slide 13: 2025 - Bio-Gene Awarded U.S. Department of Defense Grants Totalling A$3.0m
2025 - Bio-Gene Awarded U.S. Department of Defense Grants Totalling A$3.0m Deployed Warfighter Protection (DWFP) program - new product opportunities in defense The DWFP program is a U.S. Department of Defense program administered by the U.S. Armed Forces Pest Management Board that supports developme
Slide 14: Recent Milestones & News flow
Recent Milestones & News flow 14 November 2025 3 March 2026 16 March 2026 Qcide® – OMRI organic listing in the US Flavocide® regulatory development Qcide® to be launched in Japan www.bio-gene.com.au 14
Slide 15: Key Forward Milestones & News Flow
Key Forward Milestones & News Flow Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow. Strategic priorities: (1) Speed (2) Focused product development (3) Commercial validation (4) Efficient use of capital 01 02 03 Flavocide & Qcide deve
Slide 16: Global Agriculture Biological Sector - Major Licensing/Collaboration Deals
Global Agriculture Biological Sector - Major Licensing/Collaboration Deals Multinational companies seeking all-round collaborations to maximize resources & portfolio offerings Licensee Licensors Activity Uses Timing • Joint • Crop Protection • April 2023 • Biotalys development of biosolutions • Fall
Slide 17: Global Agriculture Biological Sector - Major Acquisition Deals
Global Agriculture Biological Sector - Major Acquisition Deals The biologicals category has seen a large number of acquisitions – to position for the future Year Acquiring Company Target Company Major components 2026 - AgBiTech • Biological insect control 2024 & 2025 - Agroquimica • Key biological c
Slide 18: Experienced Board of Directors & Management Team
Experienced Board of Directors & Management Team A team with strong experience in product development, partnering and commercialisation. Alex Ding Andrew Guthrie Tim Grogan Drew Speedy Chairman Non-Executive Director MD & CEO CFO & Company Secretary Previously partner at two law firms and 32 years’
Slide 19: Capital Structure
Capital Structure 12-Month Share Price Performance Key metrics 21 May 2026 0.045 18 0.04 16 ASX code BGT 0.035 14 0.03 12 Share Price A$ Share price $0.029 Volume M 0.025 10 0.02 8 Market Capitalisation ~A$8.8m 0.015 6 Shares on issue 305,061,108 0.01 4 0.005 2 Options on issue(a) 110,070,192 0 0 05
Slide 20: Contact
Contact Tim Grogan Managing Director & CEO bgt.info@bio-gene.com.au Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420 Bio-Gene Technology Limited (ABN 32 071 735 950) www.bio-gene.com.au 20
Bio-Gene Technology — Investor Presentation (May 2026) on 6ix